X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with JUBILANT LIFE SCIENCES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA JUBILANT LIFE SCIENCES NATCO PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 30.7 26.3 116.7% View Chart
P/BV x 23.3 5.4 430.6% View Chart
Dividend Yield % 0.5 0.3 146.1%  

Financials

 NATCO PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
JUBILANT LIFE SCIENCES
Mar-14
NATCO PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs877187 469.5%   
Low Rs42465 650.5%   
Sales per share (Unadj.) Rs223.4364.3 61.3%  
Earnings per share (Unadj.) Rs31.16.8 453.8%  
Cash flow per share (Unadj.) Rs40.324.5 164.4%  
Dividends per share (Unadj.) Rs5.003.00 166.7%  
Dividend yield (eoy) %0.82.4 32.3%  
Book value per share (Unadj.) Rs219.5164.9 133.1%  
Shares outstanding (eoy) m33.07159.28 20.8%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.90.3 841.9%   
Avg P/E ratio x20.918.4 113.8%  
P/CF ratio (eoy) x16.15.1 314.1%  
Price / Book Value ratio x3.00.8 387.9%  
Dividend payout %16.143.8 36.7%   
Avg Mkt Cap Rs m21,50420,061 107.2%   
No. of employees `000NA6.2 0.0%   
Total wages/salary Rs m1,12811,052 10.2%   
Avg. sales/employee Rs ThNM9,383.0-  
Avg. wages/employee Rs ThNM1,786.9-  
Avg. net profit/employee Rs ThNM176.3-  
INCOME DATA
Net Sales Rs m7,38958,034 12.7%  
Other income Rs m167191 87.7%   
Total revenues Rs m7,55658,224 13.0%   
Gross profit Rs m1,7935,786 31.0%  
Depreciation Rs m3042,812 10.8%   
Interest Rs m3663,237 11.3%   
Profit before tax Rs m1,290-72 -1,788.9%   
Minority Interest Rs m46-286 -16.2%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m309696 44.3%   
Profit after tax Rs m1,0271,090 94.2%  
Gross profit margin %24.310.0 243.4%  
Effective tax rate %23.9-965.9 -2.5%   
Net profit margin %13.91.9 740.0%  
BALANCE SHEET DATA
Current assets Rs m3,68129,280 12.6%   
Current liabilities Rs m3,12338,912 8.0%   
Net working cap to sales %7.6-16.6 -45.5%  
Current ratio x1.20.8 156.7%  
Inventory Days Days8984 106.1%  
Debtors Days Days5951 115.8%  
Net fixed assets Rs m7,68555,712 13.8%   
Share capital Rs m331155 214.0%   
"Free" reserves Rs m6,67020,968 31.8%   
Net worth Rs m7,25926,265 27.6%   
Long term debt Rs m95517,169 5.6%   
Total assets Rs m11,95788,606 13.5%  
Interest coverage x4.51.0 462.5%   
Debt to equity ratio x0.10.7 20.1%  
Sales to assets ratio x0.60.7 94.3%   
Return on assets %11.74.9 238.6%  
Return on equity %14.24.2 340.9%  
Return on capital %20.711.6 179.2%  
Exports to sales %39.437.8 104.1%   
Imports to sales %5.716.5 34.6%   
Exports (fob) Rs m2,90821,933 13.3%   
Imports (cif) Rs m4219,567 4.4%   
Fx inflow Rs m3,44522,004 15.7%   
Fx outflow Rs m70311,749 6.0%   
Net fx Rs m2,74310,255 26.7%   
CASH FLOW
From Operations Rs m1,4408,026 17.9%  
From Investments Rs m-1,089-1,744 62.4%  
From Financial Activity Rs m-353-4,447 7.9%  
Net Cashflow Rs m-11,834 -0.1%  

Share Holding

Indian Promoters % 52.0 45.6 114.1%  
Foreign collaborators % 1.5 3.5 42.0%  
Indian inst/Mut Fund % 7.8 8.7 90.1%  
FIIs % 16.6 21.2 78.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 21.1 123.2%  
Shareholders   25,395 23,815 106.6%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT LTD.  AUROBINDO PHARMA  

Compare NATCO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jan 23, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS